Spyre Therapeutics Inc. SYRE shares are up on Monday following the announcement of positive results from the Phase 2 SKYLINE trial for SPY001, which met its primary endpoint with a statistically ...
Salt-inducible kinase 2 (SIK2) is a serine/threonine kinase that regulates transcriptional programs in myeloid cells by phosphorylating transcriptional coregulators. In macrophages, SIK2 promotes the ...
Intestinal ultrasound (IUS) is non-invasive, cost-effective, and accurate to determine disease activity in ulcerative colitis (UC). In this study, we prospectively evaluated IUS for treatment response ...
Spyre Therapeutics’ monoclonal antibody hit the key goal of a phase 2 study in ulcerative colitis (UC), which the company has touted as proof it can best Takeda’s Entyvio. The mid-stage trial ...
DDW Anti-Adhesion Molecule Sticks in Ulcerative Colitis The investigational mucosal addressin cell adhesion molecule met its primary and secondary end points in the TURANDOT trial and does not appear ...
Why Do People Get a Colonoscopy for Ulcerative Colitis? Ulcerative colitis is a type of inflammatory bowel disease that causes inflammation and sores to form in the large intestine and rectum. It ...
In this Journal feature, information about a real patient is presented in stages (boldface type) to an expert clinician, who responds to the information by sharing relevant background and reasoning ...
How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results